Kezar Life Sciences, Inc. (KZR)
May 11, 2026 - KZR was delisted (reason: acquired by AUPH)
7.29
0.00 (0.00%)
Inactive · Last trade price on May 8, 2026
Kezar Life Sciences Employees
Kezar Life Sciences had 9 employees as of December 31, 2025. The number of employees decreased by 46 or -83.64% compared to the previous year.
Employees
9
Change (1Y)
-46
Growth (1Y)
-83.64%
Revenue / Employee
n/a
Profits / Employee
-$5,025,889
Market Cap
53.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 9 | -46 | -83.64% |
| Dec 31, 2024 | 55 | -3 | -5.17% |
| Dec 31, 2023 | 58 | -26 | -30.95% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 9 | 19.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
KZR News
- 21 days ago - Kezar Life Sciences Quarterly report: Q1 2026 - Filings
- 2 months ago - Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire
- 2 months ago - Kezar Life Sciences Annual report: Q4 2025 - Filings
- 2 months ago - Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences - Business Wire
- 5 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
- 7 months ago - Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire
- 7 months ago - Kezar Life Sciences Earnings release: Q3 2025 - Filings
- 7 months ago - Kezar Life Sciences Quarterly report: Q3 2025 - Filings